U.S. May Drop Daily Drink Limits in New Dietary Guidelines

According to sources familiar with the matter, the next edition of the U.S. Dietary Guidelines—due later this month—will likely eliminate the long-held recommendation that women limit themselves to one drink a day and men to two drinks a day.

Instead of explicit serving limits, the new guidelines are expected to include only brief, general language urging Americans to consume alcohol “in moderation” because of associated health risks. The traditional numerical limits might still appear in companion documents but will no longer be front-and-center.

The shift stems from mounting doubts about the scientific support for set drinking limits. Some studies highlight modest cardiovascular benefits at low alcohol levels; others point to increased cancer risks—even at one to two drinks per day. A growing body of research by authorities like the Surgeon General warns all levels of drinking carry cancer risks for conditions including breast, liver, and colon cancers.

Public health voices—including former Surgeon General Vivek Murthy—argue for clear messaging and mandatory warning labels on alcohol products. These voices emphasize transparency around cancer links and long-term risks.

In contrast, major industry players like Diageo and Anheuser-Busch InBev have invested heavily to preserve current limits. The upcoming guidelines are being watched by these firms and lawmakers aligning with their interests.

International guidelines vary:

• The UK couches its advice around weekly limits.
• Canada warns health risks begin after just two drinks per week.
• The WHO maintains no amount of alcohol is risk-free, aligning with emerging caution in many nations.

If confirmed, this is the first major change to alcohol recommendations in decades—shifting from precise “1‑for‑women/2‑for‑men” rules to a less defined approach urging moderation. Proponents worry this weakens public messaging on health risks, while the alcohol industry sees a victory. As research continues to highlight cancer risk even at low levels, the debate underscores a clash between economic interests and health scienc